These innovative therapies, including Semaglutide , belong to a group of drugs called GLP-1 mimics . Originally approved for treating diabetes mellitus , they function by encouraging the pancreas to secrete sufficient insulin and curbing increased sugar levels. Additionally , their capacity to en